The University of North Carolina at Chapel Hill

Albert Einstein College of Medicine

Research, Incorporated

Victoria Link Limited

Michael R Knowles

Richard C Boucher

Wanda Kay O'Neal

Steven Isaacman

Andrew B Mahon

Charles R Esther, Jr

Deepika Polineni

John T Gatzy

This invention relates generally to the use of 5'-methylthioadenosine phosphorylase (MTAP) inhibitors for the treatment of lung diseases associated with inflammation, such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Small molecule inhibitors of MTAP can sustain accumulation of endogenous MTA to therapeutically beneficial levels resulting in decreased inflammation in CF and COPD.

Use of MTAP inhibitors for the treatment of lung disease

Methods are disclosed for removing retained mucus secretions from the lungs of a human subject. The method includes (1) generating an aerosol suspension of respirable solid, dry particulate amiloride, and (2) delivering by inhalation the aerosol suspension to the respiratory system of the subject. The solid particulate amiloride is comprised of particles of about 1 to 5 microns and is free of liquid amiloride particles. The aerosol suspension of respirable solid particulate amiloride is administered in an amount sufficient to achieve concentrations of amiloride on the airway surfaces of from about 10.sup.-7 to 10.sup.-3 Moles/liter. As a result of the treatment, the secretions are hydrated and more easily transported from the lung via mucociliary action. Methods are also disclosed for the treatment of cystic fibrosis in humans.

Method of administering amiloride

This disclosure describes a method of treatment of retained pulmonary secretions by the use of aerosolized suspension of amiloride.

Aerosolized amiloride treatment of retained pulmonary secretions

Growing community of inventors

Chapel Hill, NC, United States of America

Michael R Knowles